ArticleFrontiers in pharmacology2021

Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders.

Kotaro Sakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.